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ABSTRACT
We performed proteomic studies using the GRP78 chaperone-inhibitor drug AR-
12 (OSU-03012) as bait. Multiple additional chaperone and chaperone-associated 
proteins were shown to interact with AR-12, including: GRP75, HSP75, BAG2; HSP27; 
ULK-1; and thioredoxin. AR-12 down-regulated in situ immuno-fluorescence detection 
of ATP binding chaperones using antibodies directed against the NH2-termini of the 
proteins but only weakly reduced detection using antibodies directed against the 
central and COOH portions of the proteins. Traditional SDS-PAGE and western blotting 
assessment methods did not exhibit any alterations in chaperone detection. AR-12 
altered the sub-cellular distribution of chaperone proteins, abolishing their punctate 
speckled patterning concomitant with changes in protein co-localization. AR-12 
inhibited chaperone ATPase activity, which was enhanced by sildenafil; inhibited 
chaperone – chaperone and chaperone – client interactions; and docked in silico 
with the ATPase domains of HSP90 and of HSP70. AR-12 combined with sildenafil 
in a GRP78 plus HSP27 –dependent fashion to profoundly activate an eIF2α/ATF4/
CHOP/Beclin1 pathway in parallel with inactivating mTOR and increasing ATG13 
phosphorylation, collectively resulting in formation of punctate toxic autophagosomes. 
Over-expression of [GRP78 and HSP27] prevented: AR-12 –induced activation of ER 
stress signaling and maintained mTOR activity; AR-12 –mediated down-regulation 
of thioredoxin, MCL-1 and c-FLIP-s; and preserved tumor cell viability. Thus the 
inhibition of chaperone protein functions by AR-12 and by multi-kinase inhibitors 
very likely explains why these agents have anti-tumor effects in multiple genetically 
diverse tumor cell types.
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INTRODUCTION
In 2005 the Dent laboratory published studies 
which strongly argued that the PDK-1 inhibitor OSU-
03012 (licensed by Arno Therapeutics from Ohio State 
University and called AR-12) was not primarily acting 
as a PDK-1 inhibitor to radio-sensitize tumor cells [1, 2]. 
In 2006 we demonstrated that the primary mechanism 
by which AR-12 killed tumor cells was via the PKR-
like endoplasmic reticulum kinase (PERK) -dependent 
induction of endoplasmic reticulum stress signaling and 
a toxic form of autophagy which through mitochondrial 
dysfunction with the release of both cytochrome c and AIF 
and a necroptotic form of cell death [3]. 
Follow-on studies then linked the effects of AR-12 
on tumor cell biology to regulation of the chaperone 
proteins HSP90, GRP78 and HSP70 [4]. It was observed 
that AR-12 reduced the protein levels of HSP90 and 
GRP78 but stimulated HSP70 expression in a PERK-
dependent fashion, as measured using the standard 
techniques of SDS PAGE and western immuno-blotting. 
Others independently confirmed our findings regarding 
AR-12 and the induction of cytotoxic ER stress [5]. 
Finally, as AR-12 down-regulates the PERK inhibitory 
chaperone GRP78, and as the induction of toxic autophagy 
was PERK dependent, we investigated the role of reduced 
GRP78 expression caused by AR-12 in the regulation 
of drug toxicity. AR-12 did not alter the transcription of 
GRP78 to any significant extent but instead destabilized 
the GRP78 protein itself, considerably reducing its half-
life as assessed by western blotting from > 24 hours to 
approximately 10 hours [6]. Over-expression of GRP78 
prevented AR-12 induced PERK activation; autophagy 
induction, and tumor cell killing.
Our studies published in 2014 and 2015 using AR-12 
have further emphasized the importance of chaperones and 
particularly GRP78 in the cell biology effects of OSU-
03012 (AR-12). We discovered that phosphodiesterase 5 
inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) 
synergized with OSU-03012 to kill a wide variety of 
tumor cells through enhanced PERK-dependent ER 
stress and autophagy, as well as through activation of 
the death receptor CD95 (FAS-R) [7]. Similar data 
were also obtained with the parent drug of OSU-03012, 
celecoxib, and also with the multi-kinase inhibitors 
sorafenib, regorafenib and pazopanib [8, 9]. Our in vitro 
and animal based studies are now two open clinical 
trials; in all solid tumor patients (NCT02466802) where 
patients are receiving increasing once daily (QD) dosing 
with regorafenib and sildenafil; in recurrent glioblastoma 
patients (NCT01817751) where they receive sorafenib, 
sildenafil and valproate twice daily (BID).
Multiple chaperone proteins play essential roles 
in maintaining protein stability and cell signaling, most 
particularly in tumor cells which generally express much 
greater amounts of cellular protein than non-transformed 
cells. e.g. multiple myeloma cells. Thus some chaperone 
proteins, e.g. HSP90, have been the target for many 
developmental therapeutic chemists and also tumor cell 
biology researchers. In the field of virology, chaperone 
proteins, particularly GRP78 have also been recognized as 
playing essential roles in the life cycles of both DNA and 
RNA viruses [10, 11]. Based on the fact our cancer biology 
data with chaperones and OSU-03012 was congruent with 
the wider literature exploring the roles of chaperones in 
virus biology, we recently performed studies to determine 
whether OSU-03012 could alter virus reproduction 
in vitro. Using OSU-03012 or using the multi-kinase 
inhibitors sorafenib (Nexavar) and pazopanib (Votrient) 
we determined that the expression of multiple chaperones 
was rapidly reduced following drug treatment; effects that 
were magnified by sildenafil [12, 13]. Using molecular 
tools we proved that the down-regulation of GRP78 was 
an essential property of these drugs in preventing virus 
reproduction.
The present studies were initiated to determine 
whether OSU-03012 or sorafenib or pazopanib altered the 
expression/localization of additional chaperone proteins and 
to identify novel targets of OSU-03012 using a proteomics 
approach. Novel targets from the mass spectrometry studies 
were then tested as OSU-03012 targets in vitro and whether 
such targets regulated tumor cell biology. 
RESULTS
Treatment of HuH7 hepatoma or HT1080 sarcoma 
cells with OSU-03012 +/− sildenafil or sorafenib +/− 
sildenafil resulted in a rapid dose- and time-dependent 
reduction in the detection of the ATP binding and ATPase 
competent chaperone proteins HSP90, GRP78 and HSP70 
in fixed in situ cells as judged using immuno-fluorescence 
with 0.5% (v/v) Triton-X100 for cell permeabilization 
from a Hermes WiScan wide field microscope (Figure 1A 
and 1B). Similar changes in the apparent levels of 
HSP90, GRP78 and HSP70 were also obtained using 
immuno-fluorescence in the primary human glioblastoma 
isolates GBM5 (PDGFRα+) and GBM12 (mutant active 
full length ERBB1) (Figure 1C). Expression of dominant 
negative eIF2α blocked OSU-03012 –induced expression 
of LC3 and Beclin1 (Figure 1D). We have previously 
published that OSU-03012 and [OSU-03012 + sildenafil] 
kills tumor cells through a PERK-dependent form of 
toxic autophagy [3]. In contrast to the altered detection / 
expression levels of chaperone proteins in Figure 1A–1D 
using in situ immuno-fluorescence staining, the detection 
of the kinases ERK2 and JNK1 which are of course also 
ATP binding proteins with ATPase activity, were not 
altered by any of drug treatments at this time as judged 
using either immuno-fluorescence or SDS PAGE followed 
by traditional western blotting (Figure 2A). 
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Using antibodies raised against different epitopes 
within HSP90 and GRP78 we observed that treatment of 
cells with OSU-03012 reduced the immuno-fluorescence 
detection of GRP78 and HSP90 with antibodies raised 
against a synthetic peptide corresponding to residues 
270–300 in human GRP78 and against synthetic peptides 
surrounding E289 of human HSP90; the standard 
antibodies we have used to detect these proteins in 
multiple other manuscripts. We also observed reduced 
immuno-fluorescence using antibodies that were generated 
to recognize epitopes even nearer the NH2-termini of both 
proteins (Figure 2B). However, using antibodies generated 
against sequences in the central region, i.e. G584 in 
GRP78 and between residues 535–732 in HSP90; or in 
the COOH-termini, i.e. residues 603–617 in GRP78 and 
near the TPR acceptor site dimerization residues MEEVD 
in HSP90, modest to no alterations in the immuno-
fluorescence signal was observed. 
Using siRNA knock-down or protein over-
expression we validated that our antibodies to these 
chaperones were specifically reacting with their targets 
(Figure 2C and 2D panels to the left). In contrast to our 
data with the protein kinases ERK2 and JNK1, where data 
obtained from immuno-fluorescence and SDS PAGE/
western blotting were congruent, the detection of HSP90, 
GRP78 and HSP70 chaperone expression by immuno-
fluorescence and SDS PAGE / western blotting using the 
same antibodies at the 6h time point were not in agreement 
(Figure 2D panels to the right; cf Figure 1A–1D). 
Previously, using SDS PAGE / western blotting we 
had demonstrated that OSU-03012 destabilizes GRP78 
protein resulting in a half-life reduction from > 24 h to 
~10 h despite modestly increasing GRP78 promoter 
activity [6]. Thus to the naked eye a substantial decline 
in GRP78 levels, as assessed by western blotting, only 
became evident 6-12h after OSU-03012 exposure. This 
contrasts with the present immuno-fluorescence and 
western blot data in Figures 1A–1D and 2A–2D where 
OSU-03012 as a single agent dramatically reduces the 
immuno-fluorescence detection of HSP90, GRP78 and 
HSP70 within 6h but does not alter the signal detected by 
western blotting. As some types of cellular membrane are 
not permeabilized by Triton X-100 we examined immuno-
fluorescence staining in fixed cells after they had been 
Figure 1: Assessing chaperone expression by immuno-fluorescence and SDS PAGE / western blotting generates 
divergent data after OSU-03012 or sorafenib treatment, Part 1. (A and B) HuH7 cells and HT1080 were treated with vehicle, 
OSU-03012 (0–3.0 µM) and/or sildenafil (2 µM) for 2 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. 
Immuno-fluorescence was performed to detect the expression levels of GRP78, HSP70 and HSP90. The relative fluorescence intensity 
value from 40 different cells from each condition was determined using Hermes system software (+/− SEM). (C) GBM5 and GBM12 cells 
were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2 µM) and/or sildenafil (2 µM) for 2 h after which cells were fixed in place and 
permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of GRP78, HSP70 and HSP90. 
(D) As indicated, GBM5, GBM6 and GBM12 cells were transfected with either an empty vector plasmid (CMV) or a plasmid to express 
dominant negative eIF2α S51A. Twenty four h after transfection cells were treated with vehicle, OSU-03012 (2.0 µM) and/or sildenafil 
(2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to 
detect the expression levels of LC3 (ATG8) and Beclin1 (ATG6). 
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treated with β-cyclodextrin or with CHAPS. Treatment 
of cells with drugs followed by fixing and membrane 
permeabilization with 10 mM β-cyclodextrin or 1% (w/v) 
CHAPS did not alter the apparent observed decline in 
HSP90, GRP78, HSP70 and HSP27 levels as determined 
by immuno-fluorescence (data not shown). This data, 
together with our detection data using antibodies raised 
against different epitopes in the chaperone proteins 
suggests that the tertiary structure of chaperone proteins 
may be rapidly altered by OSU-03012. Moreover, these 
data indicate that standard western blotting techniques 
involving denaturation are not optimal for detailed studies 
of how chaperone structure may vary in cells upon drug 
exposure.
We next sought to determine whether other cellular 
proteins, including those in the wider chaperone super-
family, interacted with OSU-03012. As a proteomics 
collaborator was not available at Massey Cancer Center 
we collaborated with colleagues at the NIH. At least four 
chaperone family proteins were co-precipitated by OSU-
03012 (Figure 3A). Two protein kinases and two proteins 
that regulate cellular redox status were also identified. 
Based on these discoveries we performed additional 
immuno-fluorescence studies to determine the impact of 
OSU-03012 and of sorafenib on the expression and/or 
phosphorylation and localization of these proteins. The 
expression of the small chaperone HSP27, which lacks an 
ATP binding site, was reduced by both OSU-03012 and by 
sorafenib, with our immuno-fluorescence data in general 
agreement with data generated via standard western 
blotting (Figure 3B). Based on 60X magnification images 
of the cells, HSP27 appeared to be both widely distributed 
Figure 2: Assessing chaperone expression by immuno-fluorescence and SDS PAGE/western blotting generates 
divergent data after OSU-03012 or sorafenib treatment, Part 2. (A) GBM5 and GBM12 cells were treated with vehicle, OSU-
03012 (2.0 µM) and/or sildenafil (2 µM) for 6 h after which: (a) in 96 well plates, cells were fixed in place and permeabilized using 
0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of ERK2 and JNK1; (b) cells were lysed with 
bromophenol blue buffer and subjected to SDS PAGE followed by immuno-blotting to detect the expression levels of ERK2 and JNK1. 
(B) GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2 µM) and/or sildenafil (2 µM) for 2 h after which cells were 
fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of GRP78 
and HSP90, using antibodies that recognize epitopes in the NH2-terminus; COOH-terminus; and in the middle of the proteins, as well as 
our previously utilized “usual” antibody. (C) Left: GBM5 cells were transfected with a scrambled siRNA molecule or siRNA molecules 
to knock down the expression of BAG2, GRP75, HSP75, HSP27 or GRP78. Twenty four h after transfection cells were fixed in place and 
permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of BAG2, GRP75, HSP75, 
HSP27 or GRP78, as indicated. Right: GBM5 and GBM12 cells were transfected with an empty vector plasmid (CMV) or plasmids to 
express GRP78 or HSP27. Twenty four h after transfection cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-
fluorescence was performed to detect the expression levels of HSP27 or GRP78, as indicated. (D) Left: GBM5 and GBM12 cells were 
transfected with a scrambled siRNA molecule or siRNA molecules to knock down the expression of HSP90, GRP78 or HSP70. Twenty 
four h after transfection cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect 
the expression levels of HSP90, HSP70 or GRP78, as indicated. Right: GBM5 and GBM12 cells were treated with vehicle, OSU-03012 
(2.0 µM) or sorafenib (2 µM) and/or sildenafil (2 µM) for 6 h. Cells were then lysed with bromophenol blue buffer and subjected to SDS 
PAGE followed by immuno-blotting to detect the expression levels of GRP78, HSP70, HSP90 and GAPDH. 
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in the cytosol and also in globular particulate formations 
in vehicle treated cells, whereas drug treatments abolished 
any particulate chaperone staining. In drug-dose-response 
studies OSU-03012 at a concentration of 1 µM was able to 
reduce HSP27 detection levels in three glioblastoma cell 
isolates within 3 h (Figure 3C). Using antibodies raised 
against different epitopes within HSP27 we observed that 
treatment of cells with OSU-03012 reduced the immuno-
fluorescence detection of HSP27 with an antibody that was 
raised against full-length HSP27 protein, i.e. our “usual” 
antibody; no precise epitope provided by the supplier, and 
antibodies that recognize the central region of the protein, 
i.e. amino acids 32–108, and a synthetic peptide raised 
against the COOH-terminus of the protein (Figure 3D). 
However, using an antibody specifically generated against 
the NH2-terminus of the HSP27 protein, residues 2–12, 
no apparent drug-induced alteration in the immuno-
fluorescence signal was observed. 
OSU-03012 and [OSU-03012 + sildenafil] 
treatment very modestly enhanced the stoichiometry of 
p38 MAPK phosphorylation (Figure 3E). OSU-03012 
as a single agent increased the stoichiometry of HSP27 
phosphorylation at Serine 15, but not at Serine 78 or 
at Serine 82; i.e. total expression of HSP27 declined 
whereas HSP27 phosphorylation did not alter, hence the 
stoichiometry of HSP27 phosphorylation rose. Our data 
also argues that Serine 78 phosphorylation declined after 
sildenafil exposure. Of particular note were the side-by-
side comparisons of AKT Threonine 308 phosphorylation 
and mTOR Serine 2448 phosphorylation. As we have 
previously shown for AKT Threonine 308 phosphorylation 
in these glioblastoma cells, OSU-03012 as a single agent 
had little to no obvious effect on T308 phosphorylation 
levels (Figure 3E). In contrast, OSU-03012 as a 
single agent strongly reduced mTOR Serine 2448 
phosphorylation. Thus our data argues that OSU-03012 
Figure 3: Proteomic and cell biology analyses of AR-12 interacting proteins. (A) As described in the Methods, AR-12 
conjugated via biotin to sepharose beads was used to capture proteins from a whole cell lysate and those proteins specifically associating 
with beads in an AR-12 –dependent fashion were determined after proteolytic digestion in a mass spectrometer. (B) GBM5 and GBM12 
cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which: (a) in 96 well 
plates, cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression 
level of HSP27 presented at 10X and 60X magnification; (b) cells were lysed with bromophenol blue buffer and subjected to SDS PAGE 
followed by immuno-blotting to detect the expression level of HSP27. (C) GBM5, GBM6 and GBM12 cells were treated with vehicle, 
OSU-03012 (0–3.0 µM) or sorafenib (0–3.0 µM) for 3h after which cells were fixed in place and permeabilized using 0.5% Triton X100. 
Immuno-fluorescence was performed to detect the expression level of HSP27. The relative fluorescence intensity value from 40 different 
cells from each condition was determined using Hermes system software (+/− SEM). (D) GBM12 cells were treated with vehicle, OSU-
03012 (2.0 µM) / sorafenib (2 µM) and/or sildenafil (2 µM) for 2 h after which cells were fixed in place and permeabilized using 0.5% 
Triton X100. Immuno-fluorescence was performed to detect the expression level of HSP27, using antibodies that recognize epitopes in 
the NH2-terminus; COOH-terminus; and in the middle of the protein, as well as our previously used “usual” antibody. (E) GBM5 and 
GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and 
permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the total expression level of AKT and p38 MAPK, 
and the phosphorylation levels of AKT T308; p38 MAPK; mTOR S2448; HSP27 S15; HSP27 S78; and HSP27 S82. 
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causes a greater degree of mTOR dephosphorylation 
when compared to its more modest effect on AKT 
dephosphorylation, implying that the regulation of mTOR 
activity by the drug is likely to be more biologically 
important than that of AKT.
We next examined the other two chaperone proteins 
shown to interact with OSU-03012 in Figure 3A; HSP75 
and GRP75 (Figure 4A and 4B). The expression of both 
HSP75 and GRP75 was reduced by treatment with OSU-
03012 or with sorafenib. Based on 60X magnification 
images of the cells, HSP75 appeared to be both widely 
distributed in the cytosol and also to have peri-nuclear 
staining in vehicle treated cells, whereas drug treatments 
abolished any peri-nuclear staining (Figure 4A and 4C).
BCL-2 associated athanogene (BAG) proteins are 
chaperone regulator/adaptor molecules that compete 
with the protein HIP for binding to the ATPase domain of 
HSP70 family chaperones, including HSP70, and regulate 
the trafficking of misfolded proteins to the proteasome or 
to autophagy. In our proteomic studies the protein BAG2 
associated with OSU-03012, and both OSU-03012 and 
sorafenib reduced BAG2 protein expression (Figure 5A). 
In addition, treatment of cells with OSU-03012 or 
sorafenib altered the granular/punctate staining of BAG2 
with its localization becoming more uniform. There are 
two other members of the BAG family, BAG1 and BAG3. 
Treatment of cells with OSU-03012 or sorafenib also 
reduced BAG1 and BAG3 protein expression (Figure 5B 
and 5C). The protein HSC70 interacting protein (HIP), 
together with BAG proteins regulates the ATPase activity 
and chaperone function of HSP70 family chaperones. 
OSU-03012, but not sorafenib, reduced HIP expression 
(Figure 5D). 
In protein-protein co-localization studies, where 
red staining overlapping green staining co-localizes to 
generate a yellow fluorescent signal, we noted that OSU-
03012 reduced the co-localization of BAG2 and HSP70 
and of HSP27 and HSP70 in GBM cells (reduced yellow 
staining; increased individual green and red staining) 
(Figure 6A and 6B). In a manner similar to the BAG 
proteins and HIP for HSP70; the protein AhA1 regulates 
the ATP loading of HSP90. Treatment of cells with OSU-
03012/sorafenib with or without sildenafil modestly 
reduced the detection of AhA1 by immuno-fluorescence 
(Figure 6C). In co-localization studies we noted that OSU-
03012 treatment reduced the co-localization of AhA1 and 
HSP90 in GBM cells (reduced yellow staining; increased 
green and red staining), with the AhA1 and HSP90 
association in punctate bodies decreased by drug exposure 
(Figure 6D).
HSP90 function, in addition to being regulated by 
AhA1, is also controlled by the essential co-chaperone 
Figure 4: HSP75 and GRP75 are AR-12 interacting proteins. (A) GBM5 and GBM12 cells were treated with vehicle, OSU-
03012 (2.0 µM)/sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% 
Triton X100. Immuno-fluorescence was performed to detect the expression level of HSP75 presented at 10X and 60X magnification. 
(B and C) GBM5 and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM)/sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 
h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the 
expression level of GRP75 presented at 10X and 60X magnification. 
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CDC37. CDC37 facilitates HSP90 chaperoning of cyclin 
dependent kinases, IκB kinases and eIF2α kinases, and 
is itself phosphorylated on Serine 13 by casein kinase 2 
[23, 24]. Serine 13 phosphorylation stabilizes CDC37 into 
a more compact conformation with enhanced secondary 
structure and in yeast models mutation of this site causes 
severe growth deficiency and reduced expression of 
multiple CDC37 client proteins. In co-localization studies 
we noted that OSU-03012 after a 6h treatment reduced the 
total expression and the co-localization of CDC37 with 
HSP90 in GBM cells (reduced yellow staining; increased 
green and red staining) (Figure 7A). Treatment of cells 
with [OSU-03012 + sildenafil] or [pazopanib + sildenafil] 
for 2 h did not alter total CDC37 expression but decreased 
CDC37 Serine 13 phosphorylation levels (Figure 7B).
We then performed additional analyses on other 
chaperone proteins, also at 60X magnification, to 
determine whether the localization of the chaperone 
in the cell was being altered following [OSU-03012 
+ sildenafil] treatment. In vehicle treated glioma cells 
HSP90 and GRP78 were localized in multiple small 
punctate bodies, whose staining was markedly reduced 
6h after [OSU-03012 + sildenafil] treatment (Figure 8A 
and 8B). In contrast, HSP70 and HSP40 localization 
was not altered by drug exposure (Figure 8C and 8D). 
Mitochondrial HSP70 (mtHSP70) staining in vehicle 
control cells exhibited a dense mackerel staining pattern as 
would be expected for mitochondrial localization which 
was dramatically altered after [OSU-03012 + sildenafil] 
exposure such that mitochondrial HSP70 staining occurred 
in very long vermiform projections (Figure 9A). In a 
manner reminiscent of the staining for mitochondrial 
HSP70, HSP60 and HSP10 protein staining also 
became more diffuse and vermiform after [OSU-03012 
+ sildenafil] exposure (Figure 9B and 9C). Very similar 
chaperone immuno-fluorescence data have been recently 
previously published by the Dent laboratory when treating 
tumor cells with [sorafenib + sildenafil] [22]. 
We next determined whether sorafenib, pazopanib 
and the sulfonamide analogue of OSU-03012 (AR-12), 
called AR-13, also altered our ability to detect HSP90, 
GRP78 and HSP27 by in situ immuno-fluorescence. 
As was previously observed for OSU-03012, sorafenib/
pazopanib/AR-13 reduced the immuno-fluorescence 
detection of HSP90, HSP70 and GSP78 using an NH2-
terminal specific antibody but not using antibodies 
directed against epitopes in the middle and COOH-
terminal portions of the proteins (Figure 10). As a 
single agent, regorafenib was ineffective at changing the 
immuno-fluorescence detection of the NH2-termini of 
Figure 5: BAG2 is an AR-12 interacting protein. (A) GBM5 and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM)/
sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. 
Immuno-fluorescence was performed to detect the expression level of BAG2 presented at 10X and 60X magnification. (B and C) GBM5 
and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM)/sorafenib (2.0 µM) and/or sildenafil (2 µM) for 6 h after which cells were 
fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression level of BAG1 and 
BAG3 presented at 10X magnification. (D) GBM5 and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM)/sorafenib (2.0 µM) 
and/or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was 
performed to detect the expression level of HIP presented at 10X magnification. 
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HSP90, HSP70 or GRP78 (Figures 10 and 11A). Upon 
examination of other chaperone proteins we also observed 
that sorafenib and pazopanib could reduce the detection of 
native proteins by immuno-fluorescence, an effect largely 
not present in cells treated with regorafenib (Figure 11B). 
In a dose-dependent fashion [OSU-03012 + sildenafil] 
reduced the expression of HSPH1/p105 and a protein it 
chaperones, c-MYC (Figure 12A). AR-13 and sildenafil 
also reduced the total expression and co-localization of 
p105 and c-MYC. In immuno-precipitates, [OSU-03012 
+ sildenafil] reduced the co-precipitation of c-MYC with 
p105 and of p105 with c-MYC (Figure 12B).
As heat shock proteins co-precipitated with OSU-
03012 in our proteomic studies, we investigated whether 
OSU-03012 altered chaperone ATPase activity. We 
transformed bacteria with a plasmid to make a GST fusion 
protein of the NH2-terminal portion of HSP90; the domain 
that contains the ATP binding site and ATPase activity of 
the chaperone. Equal portions of the NH2-terminal portion 
of HSP90 were subjected to ATPase activity analyses. 
OSU-03012 reduced chaperone ATPase activity, as 
measured on the isolated purified NH2-terminal HSP90-
GST protein fragment in vitro with an IC50 of ~200 nM 
in the presence of 0.1 mM ATP substrate (Figure 13A). 
Similar data were obtained with the multi-kinase inhibitor 
sorafenib and with the multi-kinase inhibitor pazopanib, 
but not the fluorinated analogue of sorafenib, regorafenib, 
or the parent compound of OSU-03012, celecoxib. 
Remarkably, AR-13 inhibited HSP90 chaperone ATPase 
activity, with an IC50 of ~40 nM. We then expressed 
tagged forms of HSP90 and HSP70 in eukaryotic cells, 
with cells treated for 1h with either vehicle or sildenafil. 
Equal portions of HSP90 and HSP70 were subjected to 
ATPase activity analyses. We found that equal quantities 
HSP90 and HSP70 proteins isolated using their engineered 
tags from sildenafil treated cells unexpectedly had near 
identical ATPase activities than those from vehicle control 
treated cells (Figure 13B and 13C). As was previously 
observed for bacterial expressed HSP90 ATPase activity; 
the ATPase activities of eukaryotic synthesized HSP90 
and HSP70 were also inhibited by OSU-03012, sorafenib 
and pazopanib; but were not inhibited by regorafenib. 
For OSU-03012, sildenafil enhanced its inhibitory effects 
against both the HSP90 and HSP70 ATPase activities. 
For sorafenib, sildenafil enhanced its inhibitory effects 
against both the HSP90 and HSP70 ATPase activities. 
Figure 6: AR-12 disrupts the co-localization of chaperones with their regulatory proteins. (A and B) GBM5 and GBM12 
cells were treated with vehicle control or with OSU-03012 (2 µM) for 6 h after which cells were fixed in place and permeabilized using 
0.5% Triton X100. Immuno-fluorescence was performed to detect the co-localization of HSP70 and BAG2; and HSP70 and HSP27; 
presented at 60X magnification. (C) GBM5 and GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2.0 µM) and/
or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was 
performed to detect the expression level of AhA1 presented at 10X magnification. (D) GBM12 cells were treated with vehicle control or 
with OSU-03012 (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence 
was performed to detect the co-localization of HSP90 and AhA1 presented at 10X and 60X magnification.
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For pazopanib, sildenafil did not further enhance its 
potent inhibition of the HSP90 ATPase but did enhance 
its inhibitory effect against the HSP70 ATPase. Pazopanib 
was a more potent inhibitor of the HSP90 ATPase activity 
than sorafenib whereas sorafenib was a more potent 
inhibitor of the HSP70 ATPase activity than pazopanib. For 
regorafenib, sildenafil did not enhance its HSP90 ATPase 
inhibitory activity but did enhance its inhibitory properties 
against the HSP70 ATPase. Perhaps most interestingly, 
the novel analogue AR-13 inhibited the ATPase activities 
associated with the HSP90 and the HSP70 chaperone 
complexes more efficaciously than it did the bacterial 
synthesized NH2-terminal portion of HSP90.
Based on the fact that sorafenib and pazopanib are 
well-known to be multi-S/T/Y kinase inhibitors we wished 
to prove or refute whether other tyrosine kinase inhibitors 
of disparate structures could also inhibit chaperone 
ATPase activities. Neither the second generation 
ERBB1/2/4 suicide inhibitor afatinib nor the Janus kinase 
1 and 2 inhibitor ruxolitinib could inhibit the ATPase 
activities associated with HSP90 or HSP70 (Figure 14A).
Nevertheless, treatment of cells with [ruxolitinib + 
afatinib] combined for 6 h did reduce the detection 
by in situ immuno-fluorescence of the NH2-termini of 
HSP90 and HSP70 (Figure 14B). These findings argue 
that ruxolitinib and afatinib may (somehow) interact with 
HSP90 and HSP70 so as to alter the tertiary conformation 
of their NH2-termini without impacting on chaperone 
ATPase function. i.e. conformation change and ATPase 
inhibition effects may be separate events.
In parallel sets of immuno-precipitates from cells 
expressing only endogenous levels of HSP90, GRP78 and 
HSP70 we determined whether OSU-03012, sorafenib, 
pazopanib or AR-13 could alter the composition of co-
precipitating chaperone and other associated proteins. The 
amount of HSP90, HSP27 and BAG2 in HSP70 immuno-
precipitates was reduced by OSU-03012 (Figure S1A). 
The amount of PERK and WASF3 in GRP78 immuno-
precipitates was reduced by OSU-03012. The amount 
of AhA1 in HSP90 immuno-precipitates was reduced 
by OSU-03012. Of particular note, less HSP70 co-
precipitated with HSP90 in the presence of OSU-03012 
that was also associated with reduced HSP70 mobility 
on SDS PAGE, an effect usually indicative of increased 
protein phosphorylation. Similar effects were observed 
when HSP27 was co-precipitated with HSP90, with 
HSP27 showing reduced SDS PAGE mobility in cells 
treated with OSU-03012 again suggestive of increased 
phosphorylation. In cells treated with pazopanib or with 
AR-13 immuno-precipitation of HSP90, GRP78, HSP70 
or HSP27 revealed that the levels of co-precipitating 
HSP90, GRP78, HSP70 or HSP27 was considerably 
reduced by each drug (Figure S1B and S1C). 
We next determined the impact of OSU-03012 on 
the elution profile from a gel filtration column of native 
chaperone protein complex. As a traditional protein 
biochemist was not available at Massey Cancer Center, we 
collaborated with a colleague in Australia. HeLa cells were 
pre-treated for 20 min with OSU-03012 then lysed, and 
clarified lysates subjected to gel filtration in the presence 
Figure 7: Drug combination treatments reduce CDC37 Serine 13 phosphorylation. (A) GBM12 cells were treated for 6 h 
with OSU-03012 (2.0 µM) and sildenafil (2.0 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. 
Immuno-fluorescence was performed to detect the expression levels of CDC37 and HSP90 and the co-localization of CDC37 and HSP90 
at 60X magnification. (B) GBM12 cells were treated with vehicle, OSU-03012 (2.0 µM) / sorafenib (2.0 µM) / pazopanib (2.0 µM) and/
or sildenafil (2 µM) for 6 h after which cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was 
performed to detect the expression level of CDC37 and the Serine 13 phosphorylation level in CDC37 presented at 10X magnification. 
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of vehicle control or OSU-03012. Treatment of cell lysates 
with OSU-03012 resulted in the chaperone protein HSP27 
eluting in lower molecular weight complexes compared 
to the chaperone elution in vehicle control treated lysates 
(Figure S2). n.b. there also appeared to be less over-
all detection of the HSP27 protein itself following gel 
filtration after OSU-03012 treatment compared to vehicle 
control, with very similar blotting detection level for the 
protein loading controls on each piece of nitrocellulose.
As a molecular modeling in silico collaborator was 
not available at Massey Cancer Center we performed 
studies with colleagues at Augusta University. In the 
absence of crystallographic or spectroscopic data, docking, 
using Autodock Vina, was done to predict the binding mode 
of OSU-03012 to HSP90 [16–31] (Figure S3A–S3C). 
Docking of OSU-03012 against an ensemble of structures 
derived by molecular dynamics (NAMD 2.10) from the 
high-resolution structure of the NH2-terminal domain of 
human HSP90 in complex with the ATP analog ACP (PDB 
ref code 3T10) yields two plausible poses. In the first pose, 
the purine binding pocket is filled by the phenanthroline 
group of OSU-03012, with the long axis oriented parallel 
to the surface of the protein. There is also a hydrophobic 
interaction between the CF3 group and the aromatic ring 
of Tyr139. The protonated amino group in the sidechain 
interacts with several hydrophilic residues in the α-helix 
flanking the ATP binding site, either Ser50 or Asp54. In 
the second pose the long axis of the phenanthroline group 
is oriented orthogonal to the protein surface. The CF3 
group makes a hydrophobic contact with the sidechain of 
Ile110, and the amino group shows similar interactions 
between Ser50 or Asp54 as in the first pose.
To understand why treatment of cells with OSU-
03012 resulted in reduced immuno-detection of the NH2-
terminal domain of HSP90 we performed accelerated MD 
of the complex between HSP90 (NH2-terminal domain 
only) and OSU-03012. Starting from the first pose, within 
a short span of simulated time (30 ns) the phenanthroline 
group flips to an orthogonal orientation to adopt the 
second pose. The amino group is seen to interact with 
several other residues besides Ser50 and Asp54, notably 
Asp102. A similar simulation was done with apo-HSP90. 
Comparing between the conformations the protein is seen 
to adopt with and without ligand, it can be seen that while 
the conformation of the β-sheets at the back of the ATP 
binding pocket remains nearly unchanged, the positions 
of the α-helices are very different. We also determined the 
distance groups of the OSU-03012 ligand and residues of 
HSP90 from the MD simulation. In Figure S3D we present 
data showing the distances between the amino group of 
OSU-03012 and residues S50, D54 and D102 of HSP90. 
In Figure S3E we present data showing the distances 
between the trifluoromethyl group of OSU-03012 and 
residues I110 and Y138 of HSP90. These structural 
alterations may account for the differences in chaperone 
reactivity using antibodies with NH2-terminal epitopes.
Figure 8: The sub-cellular distribution and morphology of chaperone complexes in cells before and after treatment 
with [OSU-03012 + sildenafil], Part 1. (A–D) GBM14 cells were treated with either vehicle control or OSU-03012 (2 µM) and 
sildenafil (2 µM) for 6 h. Cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to 
detect the expression levels of HSP90; GRP78; HSP70; and HSP40, presented at 60X magnification.
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We next determined whether OSU-03012 could 
dock into HSP70. The nucleotide-bound structure of 
HSP70 is tightly closed, but there are structures of HSP70 
in complex with nucleotide exchange factors, where the 
subdomains are enveloping the ADP less tightly. We 
applied artificial forces to the model to move the atoms 
to match a target structure, and we did the docking along 
the way from the starting structure to the target. The most 
plausible pose is attached; Figure S4A, and is just from the 
docking. The data presented in Figure S4B has the ATP 
super-imposed.  The phenanthrene group of OSU-03012 
is in the nucleotide binding pocked (the arginine residues 
in this pocket may form cation-pi interactions), the -CF3 
group forms hydrophobic interactions with one of the two 
tyrosine residues nearby, and the amino group in the side-
chain interacts with the serine residues that would bind to 
the phosphate groups of ATP.
We have published several manuscripts 
demonstrating that low concentrations of OSU-03012 
(AR-12) kills tumor cells, and that this effect is enhanced 
by the PDE5 inhibitor sildenafil. Based on our prior 
studies in this manuscript, we next determined the relative 
potency side-by-side of tumor cell killing by OSU-03012 
and by AR-13. (Figure S5). AR-13 and OSU-03012 
had similar dose-dependent abilities to kill GBM6 and 
GBM12 cells. However, when combined with sildenafil, 
AR-13 was significantly more capable of causing tumor 
cell death than OSU-03012, with concentrations as low as 
100 nM causing > 50% tumor cell death. Thus, we next 
determined whether our drug treatments altered chaperone 
– chaperone co-localization in cells in situ using antibodies 
for detection whose signal did not show alterations 
in signal strength after drug exposure. Regorafenib, 
sorafenib, pazopanib, AR-13 and OSU-03012 reduced 
the interactions between HSP70 and HSP27; HSP60 and 
HSP10; and GRP78 and GRP94 (Figure S6). Regorafenib 
did not alter the co-localization of HSP90 and HSP70. 
Sorafenib, pazopanib, AR-13 and OSU-03012 all modified 
the interaction between HSP90 and HSP70 reducing the 
numbers of punctate sites of co-localization as well as 
increasing sites of punctate staining that were green or red, 
not co-localized yellow.
In Figure 3A we demonstrated that two protein 
kinases associated with OSU-03012; ULK-1 and PLK4. 
The protein kinase ULK-1 is considered to be an essential 
gate-keeper kinase for the regulation of autophagosome 
formation, and whose activity is negatively regulated by 
Serine 757 phosphorylation by the kinase mTOR [32, 33]. 
This is of particular interest to us as we know that 
induction of a toxic form of autophagy plays a central role 
in OSU-03012 lethality. OSU-03012 or sorafenib reduced 
the phosphorylation of mTOR at Serine 2448, indicative of 
mTOR inactivation (Figure S7A). Reduced mTOR S2448 
phosphorylation correlated with reduced phosphorylation 
of ULK-1 at an accepted site of mTOR phosphorylation, 
Serine 757, as well as appearing to reduce the total 
expression of ULK-1 protein, which collectively in 
turn correlated with increased phosphorylation of the 
Figure 9: The sub-cellular distribution and morphology of chaperone complexes in cells before and after treatment 
with [OSU-03012 + sildenafil], Part 2. (A–C) GBM14 cells were treated with either vehicle control or OSU-03012 (2 µM) and 
sildenafil (2 µM) for 6 h. Cells were fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to 
detect the expression levels of mitochondrial HSP70; HSP60; and HSP10, presented at 60X magnification.
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autophagosome formation regulatory protein ATG13 at 
Serine 318 [33–35]. 
Serine 318 phosphorylation of ATG13 facilitates, 
together with other protein-protein interaction events, 
autophagosome formation. When we examined cells 
at 60X magnification to determine the localization of 
ULK-1 and ULK-1 S757 phospho-protein we noted a 
strong peri-nuclear localization and phosphorylation 
of ULK-1 (Figure S7B). Drug treatments, particularly 
those containing OSU-03012, demonstrated a marked 
reduction in the peri-nuclear staining of both ULK-
1 and ULK-1 S757. Downstream of ULK-1 we also 
explored the impact of our drug treatments at 60X on 
the localization and phosphorylation of ATGATG13 
S318. In vehicle or drug treated cells ATG13 protein 
was detected throughout the cell (Figure S7C). 
Drug treatments, particularly those containing OSU-03012, 
increased the levels of peri-nuclear staining ULK-1 S757 
concomitant with observation of increased and more 
intense punctate staining of phospho-ATG13 S318; the 
punctate staining was reminiscent of autophagosome 
vesicles detected using expression of an LC3-GFP protein. 
Transfection of GBM12 cells to express GRP78 both 
reduced basal phosphorylation levels and prevented the 
drug-induced phosphorylation of eIF2α and ATG13, 
but did not prevent drug-induced dephosphorylation of 
mTOR (Figure S7D). Transfection of GBM12 cells to 
express HSP27 prevented OSU-03012/sorafenib single 
agent -induced phosphorylation of eIF2α and ATG13, and 
prevented the OSU-03012/sorafenib single agent -induced 
dephosphorylation of mTOR (Figure S7D).
We next performed immuno-fluorescence protein 
co-localization studies to determine whether phospho-
ATG13 S318 or HSP27 / GRP78 / HSP90 co-localized 
with the autophagosome vesicle protein LC3 (ATG8) after 
drug exposure. Treatment of GBM5 and GBM12 cells for 
3 h with OSU-03012 or [OSU-03012 + sildenafil] caused 
phospho-ATG13 S318 or HSP27 to co-localize with LC3 
in punctate bodies (Figure S8A). Treatment of GBM5 
and GBM12 cells for 3h with OSU-03012 or [OSU-
03012 + sildenafil] caused GRP78 to co-localize with the 
autophagosome vesicle marker protein LC3 (Figure S8B). 
In contrast, HSP90 and LC3 did not co-associate prior 
to or after drug exposure. Thus we conclude it is the 
combined dysregulation of both GRP78 and HSP27 
that is required for drug-induced promotion of the toxic 
autophagy signal.
In addition to ULK-1, another protein kinase was 
detected in our mass spectrometry proteomic screen; Polo-
like kinase 4 (PLK4). PLK4 is localized in the nucleus 
where it is thought to regulate centriole biology within 
centrosomes during DNA synthesis. PLK4 interacts with 
the kinase BuBR1 which is localized in the kinetochore 
and BuBR1 associates with the scaffold protein BUB3 
which collectively regulate the mitotic spindle checkpoint. 
Treatment of cells with OSU-03012 or sorafenib, with or 
without sildenafil, did not significantly alter PLK4, BUB3 
or BuBR1 expression (data not shown). 
Our screen identified several proteins involved 
in reactive oxygen species detoxification: peroredoxin 
and thioredoxin. Thioredoxin is a well-known client of 
HSP90 and is also known to associate with peroredoxin, 
Figure 10: Chaperone conformation is regulated by OSU-03012. GBM12 cells were treated with vehicle or OSU-03012 
(2 µM); sorafenib (2 µM); regorafenib (2 µM); pazopanib (2 µM); AR-13 (2 µM); celecoxib (2 µM) for 2 h. Cells were fixed in place and 
permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of HSP90, GRP78 and HSP27, 
using antibodies that recognize epitopes in the NH2-terminus; COOH-terminus; and in the middle of the proteins. 
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presumably in a large chaperone complex [36–38]. HSP27 
maintains thioredoxin reductase expression activity which 
is vital to maintain thioredoxin as a reactive oxygen species 
detoxification enzyme. Treatment of cells with drugs 
modestly reduced the levels of peroredoxin (Figure S9A). 
Treatment of cells with OSU-03012 or with sildenafil 
(which generates both ROS and RNS) strongly lowered 
thioredoxin expression. Prior studies from our group have 
shown that agents which quench reactive oxygen species 
levels, such as N-acetyl cysteine, reduce the ability of 
OSU-03012 to kill tumor cells. Transfection of GBM cells 
with a plasmid to express a wild type thioredoxin protein 
suppressed the induction of reactive oxygen species caused 
by OSU-03012 treatment, and transfection to express a 
mutant inactive form of the protein caused a prolonged 
high level of ROS (Figure S9B). Forty eight hours after 
drug treatment, over-expression of thioredoxin had 
suppressed OSU-03012 killing whereas over-expression 
of the mutant protein strongly promoted drug-induced 
cell death (Figure S9C). Over-expression of HSP27 or of 
GRP78, maintained thioredoxin expression in the face of 
both drug combination treatments (Figure S9D).
We over-expressed chaperone proteins and 
determined their relative impact on the ability of our drug 
combinations to induce tumor cell death over 24 h. Over-
expression of HSP90, GRP78 or of [GRP78 + HSP27] 
or of [HSP70 + HSP27] significantly protected tumor 
cells from exposure to the toxic drug combinations 
(Figure S10A). Over-expression of all chaperones, alone 
or in combination, to some extent maintained expression 
of c-FLIP-s, MCL-1 and TRX after drug combination 
exposure (Figure S10B). Thus by inhibiting the functions 
of multiple chaperones our drug combinations reduce the 
expression of multiple cyto-protective proteins (TRX, 
c-FLIP-s, MCL-1, BCL-XL); facilitate the inactivation of 
cyto-protective signaling pathways (mTOR); and facilitate 
the activation of cyto-toxic pathways (PERK-eIF2α).
DISCUSSION
At present OSU-03012 ( AR-12) has obtained 
the orphan designation for cryptoccosis and tularaemia 
in Europe, and the licensee of OSU-03012, Arno 
Therapeutics, has entered into a cooperative research 
and development agreement with the US Army Medical 
Research Institute of Infectious Diseases for AR-12. 
Ourselves and others have shown that OSU-03012 
(AR-12) has anti-tumor activity in vitro and in vivo in 
many model systems as well as having anti-viral and 
anti-bacterial properties against organisms as diverse as 
Mumps, Measles, Influenza, Ebola, Marburg, and pan-
antibiotic resistant strains of Neisseria gonorrhea and 
Klebsiella pneumoniae. Indeed, over the last 10 years 
we have published multiple manuscripts detailing the 
cellular targets of OSU-03012 (AR-12). The “big-picture” 
conclusions we had previously made concerning the 
biology of the drug prior to the present manuscript were 
that OSU-03012 (AR-12) kills tumor cells selectively 
over non-transformed cells and does so by primarily 
inactivating and down-regulating the chaperone GRP78 
Figure 11: Modulation of HSP70 NH2-terminal detection by OSU-03012 and other drugs. (A) GBM12 cells were treated 
with vehicle or sorafenib (2 µM); regorafenib (2 µM); OSU-03012 (2 µM); AR-13 (2 µM); pazopanib (2 µM) for 2 h. Cells were fixed in 
place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of HSP70 using 
antibodies raised to detect the NH2-terminus, the central region, and COOH terminus of the protein. (B) GBM14 and GBM12 cells were 
treated with vehicle or sorafenib (2 µM); regorafenib (2 µM); pazopanib (2 µM) for 2 h. Cells were fixed in place and permeabilized using 
0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of the indicated chaperone proteins.
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which causes a prolonged intense endoplasmic reticulum 
stress response leading to high levels of autophagy flux, 
mitochondrial dysfunction and an apparent necroptotic 
form of tumor cell death. 
The present studies extend our knowledge to 
encompass proteomic analyses of AR-12 interacting 
proteins, demonstrating that multiple other chaperones 
and chaperone regulatory proteins interact with the drug 
in a manner which permits drug-dependent precipitation 
of those proteins. The most notable novel chaperone found 
to associate with AR-12, albeit indirectly due to its lack 
of a purine binding domain, and explain its mechanism 
of action, was HSP27. AR-12 was originally proposed 
to exhibit anti-tumor activity through inhibition of the 
enzyme PDK-1 within the PI3K pathway, a mechanism 
which we largely disproved in 2005 and 2006. In 2014 
and earlier in 2015 we proposed that one reason AR-12 
may have been thought to be a PDK-1 inhibitor was 
because cell surface GRP78 had been shown to play 
an intimate role in maintaining PI3K / PDK-1/AKT 
activity, and we discovered that AR-12 very rapidly 
caused breakdown of cell surface GRP78 [39–42]. Our 
present data demonstrating AR-12 mediated reductions 
in HSP27 expression and changes in its localization, 
including in autophagosomes, further strengthens this 
argument as several groups have shown that HSP27 
plays a key chaperone function in facilitating PI3K/AKT 
activation, which in turn provides a potent downstream 
anti-apoptotic signal in its own right, and through mTOR 
an anti-autophagy signal [43, 44]. That AR-12 targets 
multiple chaperone proteins whose clients play essential 
roles in maintaining anti-apoptotic signaling through 
the PI3K pathway strongly supports the use of AR-12 at 
the very least as a cancer therapeutic index modulator to 
enhance the effectiveness of standard of care therapies, 
and in the case of our data, glioblastoma multiforme. Prior 
studies from the Dent laboratory have demonstrated in 
PDX orthotopic animal models of GBM that OSU-03012 
can prolong animal survival and radio-sensitize tumors 
resulting in a further prolongation of survival [6]. 
The role of HSP27 in the regulation of other PI3K 
pathway regulated processes also connects our prior 
Figure 12. Co-localization of the NH2-terminal and COOH-terminal directed HSP70 antibodies. (A) GBM12 cells were treated with 
vehicle or [OSU-03012 (0-1.0 µM) + sildenafil (2.0 µM)] or with [AR-13 (1 µM) + sildenafil (2 µM)] for 6 h. Cells were then fixed in place 
and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the total expression and the co-localization of 
c-MYC and HSPH1/p105. (B) GBM12 cells were treated with vehicle or [OSU-03012 (2.0 µM) + sildenafil (2.0 µM)] for 30 min. Cells 
were lysed and portions subjected to immuno-precipitation for c-MYC or for HSPH1/p105, followed by SDS PAGE and western blotting 
to determine the co-precipitation of HSPH1/p105 with c-MYC and of c-MYC with HSPH1/p105. 
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studies with AR-12 to the new data in this manuscript 
[43–50]. As GRP78 and HSP27 both act to maintain PI3K 
/ AKT signaling they also could be thought to very likely 
play a key role in the regulation of the PI3K-regulated 
kinase mTOR. Our present data strongly argues that 
regulation of mTOR function by HSP27 may be of greater 
importance from a therapeutic standpoint than modulation 
of AKT. Under conditions of nutrient surplus or growth 
factor stimulation mTOR is active and both enhances cell 
proliferation and mobility but also suppresses catabolic 
processes such as macro-autophagy through inhibitory 
phosphorylation of ULK-1 (known as ATG-1 in yeast). We 
noted that AR-12 reduced the phosphorylation of mTOR 
at S2448, to a much greater extent than that of AKT 
T308, indicative of reduced mTOR kinase activity, which 
correlated with reduced phosphorylation of the inhibitory 
mTOR phosphorylation site in ULK-1, Serine 757. ULK-1 
activation concomitant with Serine 757 dephosphorylation 
was demonstrated by increased ATG13 phosphorylation 
at Serine 318, a site known to be targeted by ULK-1. 
Thus combined loss of GRP78 and HSP27 facilitates 
a reduction in mTOR activity which in turn promotes 
ULK-1 –dependent ATG13 phosphorylation and hence 
autophagosome formation. 
In previous work we had linked AR-12 effects at 
increasing autophagosome formation to reduced GRP78 
expression and in parallel the activation of PERK and 
elevated endoplasmic reticulum stress signaling. In 
transformed rodent fibroblasts, AR-12 increased the 
expression of Beclin1 and LC3 in a PERK dependent 
manner, in general agreement with the present data in 
human tumor cells showing that dominant negative eIF2 
alpha also suppressed AR-12 –induced expression of the 
autophagy regulatory, and autophagy facilitating proteins, 
Beclin1 and LC3. Furthermore, in this manuscript we 
demonstrated that AR-12 causes the co-localization of 
both GRP78 and HSP27 with LC3 in punctate bodies 
i.e. autophagosomes. Thus collectively our data from 
Figure 13: Sildenafil enhances the ATPase inhibitory effects of regorafenib, sorafenib, pazopanib, AR-13 and OSU-
03012. (A) A GST-HSP90 NH2-terminal fragment containing the ATP binding domain of the chaperone was synthesized in E. coli and 
purified from other bacterial proteins using glutathione sepharose. The GST-HSP90 NH2-terminal fragment protein was not eluted off the 
sepharose beads. Equal portions of beads were immediately aliquoted into individual wells in a 96 well plate. Beads were resuspended 
in kinase reaction buffer containing vehicle control; OSU-03012; sorafenib tosylate; regorafenib; pazopanib; AR-13; celecoxib (30 nM; 
100 nM; 300 nM; 1 µM) in triplicate, and incubated for 30 min at 37°C. The reaction was started by addition of ATP-lite substrate. The 
plate was removed from the incubator and placed into a Vector 3 plate reader to determine the luminescence of the reactions under each 
treatment condition (n = 3 (× 3) +/− SEM). (B and C) GBM12 cells were transfected with a plasmid to express HSP70-GFP or to express 
FLAG-tagged HSP90. Twenty four h after transfection cells were treated with vehicle control or sildenafil (2 µM) for 1 h. Chaperone 
proteins were immuno-precipitated using their tags in the presence of phosphatase inhibitors. Equal portions of precipitate sepharose beads 
were immediately aliquoted into individual wells in a 96 well plate. Beads were resuspended in ATPase reaction buffer containing vehicle 
control; OSU-03012; sorafenib tosylate; regorafenib; pazopanib; AR-13; (30 nM; 100 nM; 300 nM; 1 µM) in triplicate, and incubated for 
30 min at 37°C. The reaction was started by addition of ATP-lite substrate. The plate was removed from the incubator and placed into a 
Vector 3 plate reader to determine the luminescence of the reactions under each treatment condition (n = 3 (× 3) +/− SEM).
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previous work and the present studies argue that by 
modulating the function of the chaperones GRP78 and 
HSP27, regardless of the many other chaperones we also 
now know are effected by the drug, AR-12 promotes toxic 
autophagosome formation in tumor cells through two 
distinct mechanisms and thus this is why the catabolic 
process is associated with OSU-03012 –induced cell death.
HSP27 biology is also regulated by protein 
phosphorylation, with the p38 MAPK pathway causing 
increased phosphorylation at Serine 15, Serine 78 and 
Serine 82 in the chaperone [43–50]. Others have shown 
these modifications lead to the basal state high molecular 
weight oligomer complexes of HSP27 (> 700 kDa) 
disassociating into low molecular weight tetramers 
and dimers (~ 50 kDa) [45]. In the present studies 
we discovered that AR-12 caused the high molecular 
weight HSP27 complexes visible at 60X magnification 
to dissociate, which correlated with only modest levels 
of p38 MAPK phosphorylation and increased HSP27 
phosphorylation at Serine 15, but not at Serine 78, and 
marginally at Serine 82 only in GBM12 cells. It is known 
that Serine to Aspartic acid phospho-mimicking HSP27 
mutants have a decreased oligomer size, enhanced 
chaperone activity with in parallel an elevated binding 
capability of destabilized lysozyme. Very recent data 
from Jovcevski et al. has also demonstrated that the 
HSP27-S15D and HSP27-S78D/S82D proteins form 
large disperse complexes when compared with wild type 
HSP27, with a shift toward smaller oligomeric species 
[45]. The chaperoning activity of all single HSP27 
mutants was equivalent in the assays of Jovceski et al, 
as was the case for the double HSP27 mutant proteins, 
arguing that no single phospho-serine residue has a 
predominant role in regulating the chaperone activity of 
HSP27. i.e. the cumulative acquisition of one, then two, 
then three phosphorylations regulates the degree of HSP27 
oligomerization. Thus through both p38 MAPK signaling, 
as well as through a more direct interaction through 
HSP70 detected through proteomics and co-immuno-
precipitation, AR-12 modulates HSP27 biology.
Our data sets determining chaperone expression 
levels using immuno-fluorescence and western blotting 
were very often discordant. This was in contrast to our data 
with non-chaperone proteins that bound ATP and could 
hydrolyze ATP, i.e. ERK2 and JNK1. The expression and 
localization of nuclear localized PLK-4 and its chaperones 
was not altered by AR-12 or sorafenib. One possibility 
we explored for our data set differences was that upon 
treatment of cells with AR-12 (or sorafenib) chaperones 
were becoming localized inside vesicles that could not 
be solubilized with a 0.5% solution of Triton X100. 
Thus we performed studies using the complex former 
β-cyclodextrin, which additionally solubilizes Triton X100 
resistant sphingolipid membranes, as well as with CHAPS, 
Figure 14: Afatinib nor ruxolitinib have ATPase inhibitory effects against HSP90 or HSP70. (A) GBM12 cells were 
transfected with a plasmid to express HSP70-GFP or to express FLAG-tagged HSP90. Twenty four h after transfection chaperone proteins 
were immuno-precipitated using their tags. Equal portions of precipitate sepharose beads were immediately aliquoted into individual wells 
in a 96 well plate. Beads were resuspended in ATPase reaction buffer containing vehicle control; ruxolitinib; or afatinib (500 nM; 1000 nM; 
1500 nM; 2 µM) in triplicate, and incubated for 30 min at 37°C. The reaction was started by addition of ATP-lite substrate. The plate was 
removed from the incubator and placed into a Vector 3 plate reader to determine the luminescence of the reactions under each treatment 
condition (n = 3 (× 3) +/− SEM). (B) GBM12 cells were treated with vehicle or [afatinib (1 µM) and ruxolitinib (1 µM)] for 6 h. Cells were 
fixed in place and permeabilized using 0.5% Triton X100. Immuno-fluorescence was performed to detect the expression levels of HSP70 
and of HSP90 using antibodies raised to detect the NH2-termini and COOH termini of the proteins.
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a detergent used when lysing cells and isolating the active 
conformations of the BCL-2 homology domain 3 (BH3) 
proteins BAX and BAK. Neither detergent altered the 
immuno-fluorescence staining pattern of chaperones that 
was observed when using Triton X100. This argues against 
the hypothesis that OSU-03012 –induced localization 
changes into locations that prevent immuno-detection are 
occurring.
More obviously, when using antibodies raised 
against epitopes in different portions of HSP90, HSP70, 
HSP27 and GRP78 we also observed discordant data, 
using immuno-fluorescence detection. Antibodies raised 
against the ATP-binding NH2-terminal domains of 
HSP90, HSP70 and GRP78 demonstrated that OSU-03012 
treatment reduced immuno-fluorescence detection whereas 
those antibodies raised against central and COOH-
terminal epitopes remained constant or exhibited more 
modest declines in detection. Our data using bacterial 
and eukaryotic expressed chaperones also strongly 
argued that OSU-03012 was interacting with chaperone 
proteins through the ATP binding site within their ATPase 
domain. At this point it is also important to consider 
additional proteomic data, where a number of other ATP, 
GTP and nucleotide binding proteins were identified in 
our proteomic screen using OSU-03012, though notably 
not PDK-1 (Figure S11). Some of the proteins listed in 
Figure S11 are known to have chaperone partners, such 
as HSP90 and RAS proteins [51]. That so many proteins 
in the proteomic screen with AR-12 either bind ATP/
GTP/nucleotides, together with our in silico docking data, 
tends to argue that AR-12 is able to interact with some 
conserved structural portion of a purine binding site n.b. 
no pyrimidine specific binding protein was identified. 
Thus our present findings suggest that AR-12 treatment 
modifies the tertiary structure of ATP binding chaperones 
to such an extent that NH2-terminal antibody recognition 
epitopes become lost when examining the native protein 
and only become available for detection again after boiling 
in SDS and detection by western blot. 
The chemical structures of OSU-03012 (AR-12); 
celecoxib; sorafenib; regorafenib; pazopanib; and AR-13 
are presented in Figure S12, alongside those of guanosine, 
adenosine, cytidine, thymidine and uridine. That the 
inclusion of a single fluorine atom in sorafenib, which results 
in the drug regorafenib, should so significantly reduce the 
HSP90 ATPase inhibiting effect of the drug argues that the 
additional fluorine atom either induces a steric clash or alters 
the conformation of the ring system so much as to prevent 
chaperone association. Our initial exploratory ATPase 
studies used OSU-03012, sorafenib and regorafenib. To 
our surprise we then discovered that pazopanib was a more 
potent ATPase inhibitor than OSU-03012, whereas celecoxib 
was found to be a very poor ATPase inhibitor. When we 
compared the structures of OSU-03012, its parent drug 
celecoxib, sorafenib and pazopanib we noted that sorafenib, 
OSU-03012 and pazopanib all contained complex extended 
long ring structures including nitrogen atoms in the ring 
systems, as observed for nucleotides (dashed green circles). 
Both pazopanib and celecoxib contain sulfone moieties 
(dashed red circles). Thus a priori to any experiment we 
predicted, based on its structure including portions of the 
other ATPase inhibitors that the novel compound AR-13 
would be an HSP90 ATPase inhibitor. We subsequently 
discovered that AR-13 was significantly more potent at 
inhibiting chaperone ATPase activity than either pazopanib 
or OSU-03012. AR-13 is, in essence, the drug celecoxib 
with a phenanthrene group in place of the p-tolyl group. 
(dashed purple circles). As AR-13 is a significantly better 
HSP90 and HSP70 ATPase inhibitor than celecoxib we thus 
conclude that the phenanthrene system in AR-12 and in 
AR-13 is essential for their enhanced biological activities 
toward HSP90 and HSP70 chaperone ATPase activities 
compared to their parent compound celecoxib. 
As our studies were nearing completion a molecular 
modeling group in India published computer generated 
structures of OSU-03012 interacting with the ATPase sites 
of GRP78 and HSP70 [52]. These studies focused on polar 
hydrogen bonding interactions between OSU-03012 and the 
chaperone proteins, ignoring any hydrophobic interaction 
through the phenanthrene group. Based on the modeled 
energies of association/dissociation of OSU-03012 with 
the chaperones these authors concluded that OSU-03012 
would not alter the conformation of the HSP70 or GRP78 
chaperone proteins. Our data examining the NH2, middle and 
COOH portions of HSP90 shows that this chaperone does 
alter its 3-dimensional structure, of the NH2-terminus, in 
response to OSU-03012 exposure, and our data comparing 
the ATPase inhibitory effects of our compounds localized the 
long hydrophobic three ring C6 structure as a key molecular 
motif for chaperone inhibition. Based on in silico docking 
studies we found that OSU-03012 could associate with the 
HSP90 hydrophobic purine pockets of these chaperones. 
Studies beyond the remit of this manuscript will be required 
to fully model the association of AR-12 with purine binding 
sites in chaperone and other proteins. 
MATERIALS AND METHODS
Materials
OSU-03012, sildenafil, regorafenib, pazopanib, 
sorafenib tosylate were purchased from Selleckchem 
(Houston, TX). OSU-03012 (AR-12) and AR-13 were 
kindly provided by Arno Therapeutics (Flemington NJ). 
Cells were purchased from the ATCC and were not further 
validated beyond that claimed by ATCC. Cells were 
re-purchased every ~6 months. Primary human 
glioblastoma (GBM) cells, developed by Dr. C.D. James 
when at the Mayo Clinic (Rochester, MN) has been 
described previously [6–9]. ADOR non-small cell lung 
cancer cells are personal a donation from the patient to 
the Dent laboratory. De novo cisplatin resistant “Spiky” 
ovarian cancer cells, a patient derived explant (PDX) 
model, were kindly provided by Dr. Karen Paz (Champions 
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Oncology, NJ). The plasmid to express GRP78 was 
kindly provided to the Dent laboratory by Dr. A.S. Lee 
(University of Southern California Los Angeles, CA). 
The plasmids to express thioredoxin (TRX) and mutant 
thioredoxin (mTRX) were a kind gift from Dr. David Gius 
(Radiobiology Branch, National Cancer Institute, Bethesda, 
MD). The plasmids to express HSP27, eIF2α S51A, kinase-
inactive PERK and all others listed in this manuscript were 
purchased from Addgene (Cambridge, MA). Commercially 
available validated short hairpin RNA molecules to knock 
down RNA/protein levels were from Qiagen (Valencia, 
CA) or were supplied by collaborators [12, 13].
Methods
Protein detection
Cell treatments, SDS-PAGE and Western 
blot analysis. Cells were treated with various drug 
concentrations, as indicated in the figure legends. SDS-
PAGE and immunoblotting was performed as described 
in references [6–9]. For SDS-PAGE and immunoblotting, 
cells were plated at 5 × 105 cells/cm2 and treated with 
drugs at the indicated concentrations and after the 
indicated time of treatment, lysed in whole-cell lysis 
buffer (0.5 M Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 
1% β-mercaptoethanol, 0.02% bromophenol blue), and the 
samples were boiled for 30 minutes. The boiled samples 
were loaded onto 10–14% SDS-PAGE and electrophoresis 
was run overnight (10–100 μg/lane based on the gel size). 
Proteins were electrophoretically transferred onto 0.22-μm 
nitrocellulose, and immunoblotted with various primary 
antibodies against different proteins. Antibodies used 
include: HSP90 (E289) (Cell Signaling); HSP90 (#2928) 
(Abcam); HSP90 (ab195575) Abcam; HSP90 3G3 (13495) 
(Abcam); GRP78 (50b12) (31772) (Cell Signaling); 
GRP78 (ab191023) Abcam; GRP78 (ab103336) Abcam; 
GRP78 (N-20) (sc-1050) Santa Cruz; HSP27 (G31) 
(2402P) Cell Signaling); HSP27 [EP1724Y] (ab62339) 
Abcam; HSP27 (H-77) (sc-9012) Santa Cruz; HSP27 
(LS-C31836) Lifespan science Corp. Other antibodies were 
as used in prior studies by the laboratory. All immunoblots 
were initially visualized at 75 dpi using an Odyssey 
infrared imager (Li-Cor, Lincoln, NE), then processed at 
9999 dpi using Adobe Photoshop CS6. For presentation, 
immunoblots were digitally assessed using the provided 
Odyssey imager software. Images have their color removed 
and labeled figures generated in Microsoft PowerPoint.
Cell death measurements by live/dead assay
Cells were grown in 96-well plates with each well 
containing ~10,000 cells in 200 micro-liters of media. Cells 
were treated with the indicated concentrations of drugs for 
the indicated amounts of time in each panel. Plates were 
then centrifuged (500 rpm, 5 min) to re-adhere floating dead 
cells to the base of each well. The media was removed and 
live/dead assay reagent added and cells incubated for 10 
min before the reagent was removed. Cells were imaged 
in a Hermes WiScan instrument under 10× magnification. 
Green cells = viable; yellow/red cells = dying/dead. The 
numbers of viable and dead cells were counted manually 
from three images taken from each well combined with data 
from another two wells of separately treated cells (i.e. the 
data is the mean cell dead from 9 data points +/− SEM from 
three separate exposures).
Proteomic/mass spectrometry procedures
Preparation of biotin-AR-12
The strategy used to covalently link biotin to AR-12 
exploited structure-activity relationships established by 
the Chen laboratory. Briefly, a biotin-linker arm conjugate 
(NHS-PEG12-biotin) was added to a region of the 
compound that was not associated with biological activity; 
its relatively long length was selected to minimize potential 
interference with the compound’s active sites.
The linker arm has this structure:
The synthetic scheme is:
This scheme yields the following final biotin-AR-12 
conjugate:
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Sample preparation, SDS-PAGE and tandem 
mass spectrometry analysis
Cultured SKBR3 HER2+ human mammary 
carcinoma cells were extracted after 24 h in serum 
free medium with ice cold buffer containing non-ionic 
detergent (Triton X100), protease and phosphatase 
inhibitors. Lysates were cleared of insoluble material 
by centrifugation. Supernatants were “pre-cleared” of 
molecules that bind non-specifically to streptavidin 
(SA) coated beads by incubating with SA-beads for 30 
min at 4°C and subsequently removing the beads by 
centrifugation. Supernatant samples resulting from this 
step were then incubated with biotin-AR-12 in the presence 
or absence of excess AR-12 for 2 h at 4°C. SA-beads 
were then added for an additional 2 h at 4°C before capture 
by centrifugation, repeated washing with non-ionic 
detergent buffer and extraction with boiling Laemmli SDS-
PAGE sample buffer. Samples were subjected to SDS-
PAGE and bands were visualized using Ponceau S. Bands 
present in the biotin-AR-12 samples that were not found 
in the samples incubated with excess unlabeled AR-12 
were excised from the gel, rinsed to remove Ponceau S 
and digested with trypsin. Eluted tryptic peptides were 
separated by nanotrap- and C18-column HPLC coupled 
to online analysis by tandem mass spectrometry (nLC-
ESI-MS/MS) on an ion trap mass spectrometer equipped 
with a nanospray ion source using conventional techniques 
(Laboratory of Proteomic and Analytical Technologies, 
Frederick National Laboratory for Cancer Research, 
National Cancer Institute, Frederick, MD). The resulting 
MS/MS spectra were searched against the human IPI 
database to derive probable peptide amino acid sequence, 
protein/gene identities and statistical confidence values 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi).
Isolation of GST-NH2 terminal HSP90 from 
bacteria and the measurement of its ATPase 
activity
E. coli BL21 [F–, ompT, hsdS (rB, mB ), gal] were 
transformed with a plasmid to express a fusion protein of 
the NH2-terminal portion of HSP90 fused to glutathione-
S-transferase (GST) (purchased from Addgene). Bacteria 
were grown at 24°C with shaking until the A600 reached 
0.6. IPTG was added to a final concentration of 0.1 mM 
and the incubation continued for an additional 6 hours. 
Bacteria were recovered by centrifugation and stored on 
ice. The cell pellet was resuspended in 50 µl of ice-cold 
1X PBS per ml of culture. The re-suspended cells were 
mechanically disrupted using a probe sonicator, on ice, 
in short 5 second bursts. Triton X-100 was added to a 
final concentration of 1% (v/v) followed by 30 minutes 
of gentle shaking to aid in solubilization of the fusion 
protein. Bacterial debris and denatured proteins were 
removed by centrifugation at 15,000 × g for 20 min at 4°C. 
The supernatant was removed and immediately mixed 
with pre-equilibrated Glutathione Sepharose 4B (2 ml of 
a 50% Sepharose slurry is mixed with 100 ml of clarified 
bacterial sonicate). The Sepharose slurry was gently 
rotated in a cold room for 30 min. The slurry mixture was 
centrifuged (10,000 × g for 10 min) and the supernatant 
discarded. The Glutathione Sepharose was washed with 
10 bead volumes of 1X PBS. The Sepharose slurry was 
centrifuged (5,000 × g, 5 min), and the supernatant 
discarded. The Sepharose beads were washed three times. 
Chaperone ATPase activity using the ATPlite 1step kit 
(PerkinElmer) was determined using GST-NH2 terminal 
HSP90 still linked to the Glutathione Sepharose 4B beads. 
The Sepharose beads were equilibrated in the reaction 
buffer provided by the manufacturer for 30 min with 
gentle mixing, and the beads recovered by centrifugation. 
The beads were then resuspended 1:1 with reaction buffer. 
To each well of a 96 well plate was added 50 µl of bead 
slurry and 50 µl of substrate buffer solution containing 
vehicle control or drug to achieve the desired final drug 
concentrations. The reactions were started using a multi-
channel pipette delivering 50 µl of reconstituted reagent to 
each well. The plate was placed in foil in an orbital shaker 
at 37°C for 15 min. The plate was removed, centrifuged 
to remove floating Sepharose beads, and 100 µl of the 
supernatant from each well placed into a new well in 
another 96 well plate. The light emitted from each well/
treatment condition was quantified using a Vector 3 plate 
reader (n = 3 of three studies +/− SEM).
Assessment of reactive oxygen/nitrogen species 
generation
GBM12 cells were transfected with empty vector 
(CMV) or with plasmids to express wild type thioredoxin 
(TRX) or a mutant inactive thioredoxin (mTRX), and 
24 h after transfection cells were re-plated into 96-well 
plates. Cells were treated with 1 µM OSU-03012 for the 
indicated periods. Fifteen minutes before isolation, cells 
were incubated with 2′,7′-dichlorodihydrofluorescein 
diacetate (dihydro-DCF; Invitrogen) (5 μM), which is 
non-fluorescent in its dihydro form but upon reaction with 
reactive oxygen (ROS)/nitrogen species becomes highly 
fluorescent. Dihydro-DCF is sensitive to oxidation by 
hydroxyl radicals and peroxynitrite directly and hydrogen 
peroxide in the presence of a peroxidase. Fluorescence 
measurements were obtained 15 min after OSU-03012 
addition with a Vector 3 plate reader. Data are presented 
corrected for baseline fluorescence of dye at each time 
point. Each time point represents the mean of six data 
points.
Gel filtration of HeLa cell lysates
HeLa cells were grown in 25 cm2 flasks were 
exposed to AR-12 or sorafenib (both, 5 µM) or DMSO 
control for 20 mins. Media was removed and cells washed 
with PBS containing 5 µM of drug (or equivalent volume 
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of DMSO) two times. Cells were lysed with 1% Triton 
X-100 in PBS containing protease and phosphatase 
inhibitors (Pierce) and 5 µM of drug or equivalent volume 
of DMSO as a control. Samples were vortexed and then 
incubated at 4°C for 30 mins on ice. Samples were 
centrifuged (20,000 × g, 20 min, 4°C) and supernatants 
collected and stored at 4°C until they were subjected to gel 
filtration. A Superdex 10/300 column (GE Healthcare) was 
pre-equilibrated with buffer (PBS) containing 5 µM drug 
or equivalent volume of DMSO at 0.5 ml/min. 200 μg 
of total protein was loaded onto the column (100 µl of 
sample) and proteins eluted with buffer at 0.5 ml/min. 
Fractions of 1 ml were collected as they eluted from the 
column. Those fractions containing protein (8–23) were 
collected and initially stored on ice. To each fraction, 250 µl 
of ice-cold trichloroacetic acid was added to a final 
concentration of 10% (w/v) to precipitate the proteins; 
each fraction was mixed vigorously and then incubated on 
ice overnight. Samples were then centrifuged (20,000 × g, 
20 min, 4°C), the supernatant discarded and the protein 
pellet washed twice with cold acetone followed each time 
by additional centrifugations. Samples were then left to 
air-dry prior to SDS-PAGE and immunoblotting.
Molecular dynamics
The model system for HSP90 was built using 
VMD. For the model, the coordinates of human HSP90 
in complex with ACP (PDB refcode 3T10) were used. 
The protein was inserted into a cubic water box of size 
80 * 80 * 80 Å3. The whole system consisted of 
47971 atoms. For MD simulations, NAMD 2.10 was 
used. Ligand and protein were restrained to their 
original positions and the system was equilibrated at 
constant temperature and pressure (300 K, 1 atm, NPT 
ensemble) for 0.5 ns. Simulations were done using 
the CHARMM36 force-field in combination with 
the CGenFF forcefield where needed. Then 5 ns of 
production MD was performed. Docking (Autodock 
Vina) was done against conformations extracted from 
this run. Initial CGenFF-compatible parameters for 
the AR-12 were derived using the CGenFF website 
and subsequently optimized. Subsequently, 50 ns of 
accelerated MD with Generalized Born Implicit Solvent 
(GBIS) for both HSP90 in complex with AR-12 and apo-
HSP90 was performed [25–41].
Data analysis
Comparison of the effects of various treatments was 
performed using one way analysis of variance followed by 
a two tailed Student’s t-test. Experiments were performed 
in triplicate and were performed individually three times 
(± SEM). Differences with a p-value of < 0.05 were 
considered to be statistically significant. 
Abbreviations
OSU: OSU-03012 also called AR-12; SIL: sildenafil 
also called Viagra; TAD: tadalafil also called Cialis; 
PTEN: Phosphatase and tensin homolog; R: receptor; dn: 
dominant negative; CMV: empty vector control plasmid; 
COX: cyclooxygenase; P: phospho-; ca: constitutively 
active; WT: wild type; PERK: PKR like endoplasmic 
reticulum kinase; HSP: heat shock protein; GRP: glucose 
regulated protein; CHAPS: 3-[(3-Cholamidopropyl)
dimethylammonio]-1-propanesulfonate.
ACKNOWLEDGMENTS
Thanks to Dr. H.F. Young (Neurosurgery, VCU) 
and the Betts family fund for support in the purchase 
of the Hermes Wiscan instrument. PD wishes to thank 
Mr. Daniel Leon (VCU personnel, Dent laboratory) for 
assistance during these studies. 
GRANT SUPPORT
Support for the present study was funded by 
philanthropic monies supplied by Massey Cancer Center 
(to PD), PD is the holder of the Universal Inc. Chair in 
Signal Transduction Research.
CONFLICTS OF INTEREST
AZ and SP are Directors of Arno Therapeutics, the 
Corporation that owns the license for OSU-03012 (AR-12) 
from Ohio State University. CSC is the inventor of OSU-
03012 and DW in the laboratory of CSC synthesized the 
biotin drug conjugate for our studies. All other authors 
have no conflicts of interest to report. 
REFERENCES
 1. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, Hong Y, 
Hawkins W, Sasazuki T, Shirasawa S, Kozikowski AP, 
Dennis PA, Hagan MP, Grant S, et al. Activated forms 
of H-RAS and K-RAS differentially regulate membrane 
association of PI3K, PDK-1, and AKT and the effect of 
therapeutic kinase inhibitors on cell survival. Mol Cancer 
Ther. 2005; 4:257–70.
 2. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, 
Shaw YJ, Kulp SK, Chen CS. From the cyclooxygenase-2 
inhibitor celecoxib to a novel class of 3-phosphoinositide-
dependent protein kinase-1 inhibitors. Cancer Res. 2004; 
64:4309–18.
 3. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, 
Pandya AP, Harada H, Powis G, Chen CS, Koumenis C, Grant S, 
Dent P. OSU-03012 promotes caspase-independent but 
PERK-, cathepsin B-, BID-, and AIF-dependent killing of 
transformed cells. Mol Pharmacol. 2006; 70:589–603.
Oncotarget12995www.impactjournals.com/oncotarget
 4. Park MA, Yacoub A, Rahmani M, Zhang G, Hart L, Hagan MP, 
Calderwood SK, Sherman MY, Koumenis C, Spiegel S, 
Chen CS, Graf M, Curiel DT, et al. OSU-03012 stimulates 
PKR-like endoplasmic reticulum-dependent increases 
in 70-kDa heat shock protein expression, attenuating its 
lethal actions in transformed cells. Mol Pharmacol. 2008; 
73:1168–84.
 5. Gao M, Yeh PY, Lu YS, Hsu CH, Chen KF, Lee WC, Feng WC, 
Chen CS, Kuo ML, Cheng AL. OSU-03012, a novel 
celecoxib derivative, induces reactive oxygen species-
related autophagy in hepatocellular carcinoma. Cancer Res. 
2008; 68:9348–57.
 6. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, 
Chen CS, Grant S, Dent P. OSU-03012 suppresses GRP78/
BiP expression that causes PERK-dependent increases in 
tumor cell killing. Cancer Biol Ther. 2012; 13:224–36.
 7. Booth L, Roberts JL, Cruickshanks N, Grant S, Poklepovic A, 
Dent P. Regulation of OSU-03012 toxicity by ER stress 
proteins and ER stress-inducing drugs. Mol Cancer Ther. 
2014; 13:2384–98.
 8. Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, 
Chuckalovcak J, Poklepovic A, Booth L, Dent P. Nexavar/
Stivarga and viagra interact to kill tumor cells. J Cell 
Physiol. 2015; 230:2281–98.
 9. Booth L, Roberts JL, Tavallai M, Nourbakhsh A, 
Chuckalovcak J, Carter J, Poklepovic A, Dent P. OSU-
03012 and Viagra Treatment Inhibits the Activity of Multiple 
Chaperone Proteins and Disrupts the Blood-Brain Barrier: 
Implications for Anti-Cancer Therapies. J Cell Physiol. 2015; 
230:1982–98.
10. Earl PL, Moss B, Doms RW. Folding, interaction with GRP78-
BiP, assembly, and transport of the human immunodeficiency 
virus type 1 envelope protein. J Virol. 1991; 65:2047–55.
11. Reid SP, Shurtleff AC, Costantino JA, Tritsch SR, Retterer C, 
Spurgers KB, Bavari S. HSPA5 is an essential host factor 
for Ebola virus infection. Antiviral Res. 2014; 109:171–4.
12. Booth L, Roberts JL, Cash DR, Tavallai S, Jean S, Fidanza A, 
Cruz-Luna T, Siembiba P, Cycon KA, Cornelissen CN, Dent P. 
GRP78/BiP/HSPA5/Dna K is a universal therapeutic target 
for human disease. J Cell Physiol. 2015; 230:1661–76. 
13. Roberts JL, Tavallai M, Nourbakhsh A, Fidanza A, Cruz-
Luna T, Smith E, Siembida P, Plamondon P, Cycon KA, 
Doern CD, Booth L, Dent P. GRP78/Dna K Is a Target 
for Nexavar/Stivarga/Votrient in the Treatment of Human 
Malignancies, Viral Infections and Bacterial Diseases. J 
Cell Physiol. 2015; 230:2552–78.
14. Liu W, Landgraf R. Phosphorylated and unphosphorylated 
serine 13 of CDC37 stabilize distinct interactions between 
its client and HSP90 binding domains. Biochemistry. 2015; 
54:1493–504.
15. Roe SM, Ali MM, Meyer P, Vaughan CK, Panaretou B, 
Piper PW, Prodromou C, Pearl LH. The Mechanism of 
Hsp90 regulation by the protein kinase-specific cochaperone 
p50 (cdc37). Cell. 2004; 116:87–98.
16. Trott O, Olson AJ, AutoDock Vina: improving the speed and 
accuracy of docking with a new scoring function, efficient 
optimization and multithreading, Journal of Computational 
Chemistry. 2010; 31:455–461.
17. Li J, Sun L, Xu C, Yu F, Zhou H, Zhao Y, Zhang J, Cai J, 
Mao C, Tang L, Xu Y, He J. Structure insights into 
mechanisms of ATP hydrolysis and the activation of human 
heat-shock protein 90. Acta Biochim Biophys Sinica 
(Shanghai). 2012; 44:300–6. 
18. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, 
Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable 
molecular dynamics with NAMD. J. Comput. Chem. 2005; 
26:1781–1802.
19. Hamelberg D, Mongan J, McCammon JA. Accelerated 
Molecular Dynamics: A promising and efficient simulation 
method for biomolecules, J. Chem. Phys. 2004; 120:11919-29.
20. Wang Y, Harrison C, Schulten K, McCammon JA. 
Implementation of Accelerated Molecular Dynamics in 
NAMD, Comp. Sci. Discov. 2011; 4:015002.
21. Humphrey W, Dalke A, Schulten K. VMD - Visual 
Molecular Dynamics. J. Molec. Graphics, 1996; 14:33–38.
22. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, Feig M, 
MacKerell Jr. AD. Optimization of the additive CHARMM 
all-atom protein force field targeting improved sampling of 
the backbone phi, psi and side-chain chi1 and chi2 dihedral 
angles. Journal of Chemical Theory and Computation. 
2012; 8:3257–3273. 
23. MacKerell Jr. AD, Bashford D, Bellott M, Dunbrack Jr. RL, 
Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, 
Joseph-McCarthy D, Kuchnir L, Kuczera K, et al. All-atom 
empirical potential for molecular modeling and dynamics 
studies of proteins. Journal of Physical Chemistry B 1998; 
102:3586–3616. 
24. Hart K, Foloppe N, Baker CM, Denning EJ, Nilsson L, 
MacKerell AD. Optimization of the CHARMM additive 
force field for DNA: Improved treatment of the BI/BII 
conformational equilibrium. Journal of Chemical Theory 
and Computation. 2012; 8:348–362.
25. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, 
Zhong S, Shim J, Darian E, Guvench O, Lopes P, Vorobyov I, 
MacKerell Jr. AD. J. Comput. Chem. 2010; 31:671–690.
26. Yu W, He X, Vanommeslaeghe K, MacKerell Jr. AD. J. 
Comput. Chem. 2012; 33:2451–2468.
27. http://cgenff.paramchem.org 
28. Vanommeslaeghe K, MacKerell Jr. AD. Automation of 
the CHARMM General Force Field (CGenFF) I: bond 
perception and atom typing, J. Chem. Inf. Model. 2012; 
52:3144–3154.
29. Vanommeslaeghe K, Raman EP, MacKerell Jr. AD. 
Automation of the CHARMM General Force Field 
(CGenFF) II: Assignment of bonded parameters and partial 
atomic charges, J. Chem. Inf. Model. 2012; 52:3155–3168.
Oncotarget12996www.impactjournals.com/oncotarget
30. Tanner DE, Phillips JC, Schulten K. GPU/CPU algorithm 
for generalized Born / solvent-accessible surface area 
implicit solvent calculations, Journal of Chemical Theory 
and Computation. 2012; 8:2521–2530.
31. Tanner DE, Chan KY, Phillips J, Schulten K. Parallel 
generalized Born implicit solvent calculations with NAMD. 
Journal of Chemical Theory and Computation. 2011; 
7:3635–3642.
32. Dunlop EA, Tee AR. mTOR and autophagy: a dynamic 
relationship governed by nutrients and energy. Semin Cell 
Dev Biol. 2014; 36:121–9.
33. Wong PM, Puente C, Ganley IG, Jiang X. The ULK1 complex: 
sensing nutrient signals for autophagy activation. Autophagy. 
2013; 9:124–37.
34. Alers S, Wesselborg S, Stork B. ATG13: just a companion, 
or an executor of the autophagic program? Autophagy. 
2014;10:944–56.
35. Stanley RE, Ragusa MJ, Hurley JH. The beginning of the 
end: how scaffolds nucleate autophagosome biogenesis. 
Trends Cell Biol. 2014; 24:73–81.
36. Floen MJ, Forred BJ, Bloom EJ, Vitiello PF. Thioredoxin-1 
redox signaling regulates cell survival in response to 
hyperoxia. Free Radic Biol Med. 2014; 75:167–77.
37. Di Domenico F, Sultana R, Tiu GF, Scheff NN, Perluigi M, 
Cini C, Butterfield DA. Protein levels of heat shock 
proteins 27, 32, 60, 70, 90 andthioredoxin-1 in amnestic mild 
cognitive impairment: an investigation on the role of cellular 
stress response in the progression of Alzheimer disease. Brain 
Res. 2010; 1333:72–81.
38. Zhang Y, Shen X. Heat shock protein 27 protects L929 
cells from cisplatin-induced apoptosis by enhancing 
Akt activation and abating suppression of thioredoxin 
reductase activity. Clin Cancer Res. 2007; 13:2855–64.
39. Ni M, Lee AS. ER chaperones in mammalian development 
and human diseases. FEBS Lett. 2007; 581: 3641–51.
40. Lee AS. GRP78 induction in cancer: therapeutic and 
prognostic implications. Cancer Res. 2007; 67:3496–9. 
41. Luo B, Lee AS. The critical roles of endoplasmic reticulum 
chaperones and unfolded protein response in tumorigenesis 
and anticancer therapies. Oncogene. 2013; 32:805–18.
42. Tsai YL, Zhang Y, Tseng CC, Stanciauskas R, Pinaud F, 
Lee AS. Characterization and mechanism of stress-induced 
translocation of 78-kilodalton glucose-regulated protein 
(GRP78) to the cell surface. J Biol Chem. 2015; 290:8049–64.
43. Li R, Li J, Sang D, Lan Q. Phosphorylation of AKT induced 
by phosphorylated Hsp27 confers the apoptosis-resistance 
in t-AUCB-treated glioblastoma cells in vitro. J Neurooncol. 
2015; 121:83–9.
44. Cayado-Gutiérrez N, Moncalero VL, Rosales EM, Berón W, 
Salvatierra EE, Alvarez-Olmedo D, Radrizzani M, 
Ciocca DR. Downregulation of Hsp27 (HSPB1) in MCF-7 
human breast cancer cells induces upregulation of PTEN. Cell 
Stress Chaperones. 2013;18:243–9.
45. Jovcevski B, Kelly MA, Rote AP, Berg T, Gastall HY, 
Benesch JL, Aquilina JA, Ecroyd H. Phosphomimics 
destabilize Hsp27 oligomeric assemblies and enhance 
chaperone activity. Chem Biol. 2015; 22:186–95.
46. Lambert H, Charette SJ, Bernier AF, Guimond A, Landry J. 
HSP27 multimerization mediated by phosphorylation-
sensitive intermolecular interactions at the amino terminus. 
J. Biol. Chem. 1999; 274:9378–9385.
47. Hayes D, Napoli V, Mazurkie A, Stafford WF, Graceffa P. 
Phosphorylation dependence of hsp27 multimeric size 
and molecular chaperone function. J. Biol. Chem. 2009: 
284:18801–18807
48. McDonald ET, Bortolus M, Koteiche HA, McHaourab HS. 
Sequence, structure, and dynamic determinants of Hsp27 
(HspB1) equilibrium dissociation are encoded by the 
N-terminal domain. Biochemistry, 2012: 51:1257–1268.
49. Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, 
Ducasse C, Wieske CPM, Arrigo AP, Buchner J, et al. 
Regulation of Hsp27 oligomerization, chaperone function, 
and protective activity against oxidative stress/tumor 
necrosis factor alpha by phosphorylation. J. Biol. Chem. 
1999; 274:18947–18956.
50. Shashidharamurthy R, Koteiche HA, Dong J, McHaourab HS. 
Mechanism of chaperone function in small heat shock 
proteins: dissociation of the HSP27 oligomer is required 
for recognition and binding of destabilized T4 lysozyme. 
J. Biol. Chem. 2005; 280:5281–5289.
51. Qi X, Xie C, Hou S, Li G, Yin N, Dong L, Lepp A, 
Chesnik MA, Mirza SP, Szabo A, Tsai S, Basir Z, Wu S, et al. 
Identification of a ternary protein-complex as a therapeutic 
target for K-Ras-dependent colon cancer. Oncotarget. 2014; 
5:4269–82. doi: 10.18632/oncotarget.2001.
52. Bhattacharjee R, Devi A, Mishra S. Molecular docking 
and molecular dynamics studies reveal structural basis of 
inhibition and selectivity of inhibitors EGCG and OSU-
03012 toward glucose regulated protein-78 (GRP78) 
overexpressed in glioblastoma. J Mol Model. 2015; 21:272.
